Manufacturing issues have caused an interruption in the manufacturing and release of medicinal products Endoxan (cyclophosphamide) 500 mg powder for solution for injection - 1 vial MA n. 015628074 and Endoxan (cyclophosphamide) 1 g powder for solution for injection - 1 vial MA n. 015628086, resulting in a shortage (quota distribution) expected to continue through Q3 2026.

Baxter S.p.A. is working with the manufacturing partner to restore normal supply as quickly as possible. The shortage is not due to any safety, efficacy or quality concern with currently available supplies of cyclophosphamide.

The supply of Baxter cyclophosphamide in tablet form is unaffected.

During this period, healthcare professionals should:

• confirm that there are adequate supplies of intravenous cyclophosphamide available to complete a treatment course before starting any new patients on treatment;
• advise concerned patients and caregivers to seek medical advice from their healthcare provider.